Stem cells derived from fat tissue will be used in clinical trials for treating rheumatoid arthritis patients starting 2015, as Belgian company TiGenix has announced recently. It will use its stem cell product Cx611 in a randomized phase II trial.
Eligible for the trial will be patients with active RA. They might undergo treatment with methotrexate and steroids, but not with biologics.
The aim of the trial will be to test whether the use of stem cell product can lead to remission which is defined as a Disease Activity Score in 28 joints below 2.6.
In order to reduce the necessity of use of lifelong and expensive biological therapies, there is urgent need in developing treatments with an alternative mechanism of action that would lead to remission in patients with rheumatoid arthritis.
As the company has announced, the results of the study will be published in the first half of 2017.
||Rezultat tretmana fetalnim matičnim ćelijama zavisi od: težine bolesti, starosne dobi pacijenta, doslednosti i privrženosti medikaciji i režimu. Rezultati tretmana, prezentovani na ovom sajtu, su individualni za svaki klinički slučaj.|